The epidemiology of malaria in sub-Saharan Africa is changing, and this is partly explained by the major increasing in mobilization of funding and at the scaling up of interventions such as the deployment of artemisinin-based combinations (ACT) or long-lasting insecticidal nets (LLIN). The opportunities for the development of new drugs and vaccines for malaria control look brighter now than 10 years ago. However, despite these early successes it is still unclear how this trend will be maintained and what new tools are needed for the (almost) complete elimination of malaria as a public health problem.
Though there are increasing reports of dramatic declines in the burden of malaria in a number of countries, its burden is still high in some areas such as Burkina Faso. In this specific context, it is extremely important to establish the safety, efficacy and effectiveness of new interventions. Nevertheless, there are few places in Africa with the necessary infrastructure and expertise where such research can be carried out at the international quality standards required. More in general, very few African research institutions, even if they have carried out GCP-compliant clinical trials in the past, have been able to maintain over time the required infrastructure and expertise as these have often been linked to specific projects with limited funding.